Simplified HIV Testing and Treatment in China: Analysis of Mortality Rates Before and After a Structural Intervention. by Wu, Zunyou et al.
UCLA
UCLA Previously Published Works
Title
Simplified HIV Testing and Treatment in China: Analysis of Mortality Rates Before and After 
a Structural Intervention.
Permalink
https://escholarship.org/uc/item/3xb972dh
Journal
PLoS medicine, 12(9)
ISSN
1549-1277
Authors
Wu, Zunyou
Zhao, Yan
Ge, Xianmin
et al.
Publication Date
2015-09-08
DOI
10.1371/journal.pmed.1001874
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
RESEARCH ARTICLE
Simplified HIV Testing and Treatment in
China: Analysis of Mortality Rates Before and
After a Structural Intervention
ZunyouWu1*, Yan Zhao1, Xianmin Ge2, Yurong Mao1, Zhenzhu Tang3, Cynthia X. Shi1,
Chi Chen2, Yong Li4, Xuejun Qiu5, Guide Nong6, Shanhui Huang7, Shen Luo8,
Shaohui Wu9, Wenzhen He10, Mingjie Zhang1, Zhiyong Shen3, Xia Jin1, Jian Li1,
Ron Brookmeyer11, Roger Detels12, Julio Montaner13, YuWang14*
1 National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and
Prevention, Beijing, China, 2 Guangxi Bureau of HIV/AIDS, Guangxi Health Department, Nanning, China,
3 Guangxi Center for Disease Control and Prevention, Nanning, China, 4 Guangxi Antiretroviral Treatment
Center, Liuzhou, China, 5 Zhongshan County Health Bureau, Zhongshan, China, 6 Zhongshan County
Center for Disease Control and Prevention, Zhongshan, China, 7 Zhongshan County General Hospital,
Zhongshan, China, 8 Pubei County Health Bureau, Pubei, China, 9 Pubei County Center for Disease
Control and Prevention, Pubei, China, 10 Pubei County General Hospital, Pubei, China, 11 Department of
Biostatistics, Fielding School of Public Health, University of California at Los Angeles, Los Angeles,
California, United States of America, 12 Department of Epidemiology, Fielding School of Public Health,
University of California at Los Angeles, Los Angeles, California, United States of America, 13 BC Centre for
Excellence in HIV/AIDS, University of British Columbia, Vancouver, British Columbia, Canada, 14 Chinese
Center for Disease Control and Prevention, Beijing, China
* wuzy@263.net (ZW); wangyu@chinacdc.cn (YW)
Abstract
Background
Multistage stepwise HIV testing and treatment initiation procedures can result in lost oppor-
tunities to provide timely antiretroviral therapy (ART). Incomplete patient engagement along
the continuum of HIV care translates into high levels of preventable mortality. We aimed to
evaluate the ability of a simplified test and treat structural intervention to reduce mortality.
Methods and Findings
In the “pre-intervention 2010” (from January 2010 to December 2010) and “pre-intervention
2011” (from January 2011 to December 2011) phases, patients who screened HIV-positive
at health care facilities in Zhongshan and Pubei counties in Guangxi, China, followed the
standard-of-care process. In the “post-intervention 2012” (from July 2012 to June 2013) and
“post-intervention 2013” (from July 2013 to June 2014) phases, patients who screened HIV-
positive at the same facilities were offered a simplified test and treat intervention, i.e., con-
current HIV confirmatory and CD4 testing and immediate initiation of ART, irrespective of
CD4 count. Participants were followed for 6–18 mo until the end of their study phase period.
Mortality rates in the pre-intervention and post-intervention phases were compared for all
HIV cases and for treatment-eligible HIV cases. A total of 1,034 HIV-positive participants
(281 and 339 in the two pre-intervention phases respectively, and 215 and 199 in the two
post-intervention phases respectively) were enrolled. Following the structural intervention,
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receipt of baseline CD4 testing within 30 d of HIV confirmation increased from 67%/61%
(pre-intervention 2010/pre-intervention 2011) to 98%/97% (post-intervention 2012/post-
intervention 2013) (all p < 0.001 [i.e., for all comparisons between a pre- and post-
intervention phase]), and the time from HIV confirmation to ART initiation decreased from
53 d (interquartile range [IQR] 27–141)/43 d (IQR 15–113) to 5 d (IQR 2–12)/5 d (IQR 2–13)
(all p < 0.001). Initiation of ART increased from 27%/49% to 91%/89% among all cases (all
p < 0.001) and from 39%/62% to 94%/90% among individuals with CD4 count 350 cells/
mm3 or AIDS (all p < 0.001). Mortality decreased from 27%/27% to 10%/10% for all cases
(all p < 0.001) and from 40%/35% to 13%/13% for cases with CD4 count 350 cells/mm3 or
AIDS (all p < 0.001). The simplified test and treat intervention was significantly associated
with decreased mortality rates compared to pre-intervention 2011 (adjusted hazard ratio
[aHR] 0.385 [95%CI 0.239–0.620] and 0.380 [95%CI 0.233–0.618] for the two post-
intervention phases, respectively, for all newly diagnosed HIV cases [both p < 0.001], and
aHR 0.369 [95%CI 0.226–0.603] and 0.361 [95%CI 0.221–0.590] for newly diagnosed
treatment-eligible HIV cases [both p < 0.001]). The unit cost of an additional patient receiving
ART attributable to the intervention was US$83.80. The unit cost of a death prevented
because of the intervention was US$234.52.
Conclusions
Our results demonstrate that the simplified HIV test and treat intervention promoted suc-
cessful engagement in care and was associated with a 62% reduction in mortality. Our find-
ings support the implementation of integrated HIV testing and immediate access to ART
irrespective of CD4 count, in order to optimize the impact of ART.
Introduction
In June 2010, the World Health Organization (WHO) and the Joint United Nations Pro-
gramme on HIV/AIDS (UNAIDS) launched the Treatment 2.0 strategy, an initiative to expand
access to HIV testing and antiretroviral therapy (ART) and to maximize the individual and
public health benefits of modern HIV treatment [1]. Global experience over the past decade
has confirmed the lifesaving benefits of ART for treating HIV-positive patients. However, late
diagnosis, incomplete linkage to care, and loss to follow-up (LTFU) remain major clinical and
public health challenges [2–4]. High rates of LTFU, before and after ART initiation, are rela-
tively common in both high- and low-resource settings [5–9]. Moreover, late initiation of ART
and high LTFU rates are significant drivers of mortality [10–13]. Despite nationwide scale-up
of HIV programs in China over the last decade, the proportion of ART-eligible HIV-positive
patients who receive treatment remains low. In 2009, it was estimated that 53.3% of HIV-
positive individuals received a baseline CD4 count test within 6 mo of diagnosis [14], and
among ART-eligible patients, treatment coverage was 63.4%, and the mortality rate was 14.2
per 100 person-years [12].
In China, as in many settings worldwide, patients are lost at each step along the continuum
of HIV testing and care. This includes patients lost after not meeting ART eligibility criteria at
the time of diagnosis. Other patients may meet treatment criteria but fail to initiate ART. Com-
plicated HIV testing policies may be contributing to early LTFU. According to the current Chi-
nese standard-of-care policies [15], CD4 testing is offered only after the HIV diagnosis has
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been confirmed through Western blot (WB) testing. This results in a structural delay to initiat-
ing ART because CD4 count is the primary measure used to determine eligibility for the Chi-
nese National Free Antiretroviral Treatment Program (NFATP).
Although published studies have described the HIV care continuum, most studies have
been either observational or focused on an intervention targeting a limited section of the HIV
care cascade, such as increasing the proportion of participants receiving CD4 testing or the
proportion initiating ART [16,17]. Strategic interventions to streamline HIV testing and treat-
ment procedures should be designed to decrease LTFU and mortality. We designed a structur-
ally simplified test and treat intervention, to be completed within a week of the first positive
HIV screening test result, incorporating immediate HIV confirmatory testing, pre-ART CD4
testing, pretreatment counseling, and ART initiation regardless of CD4 count. The aim of this
pilot study was to evaluate the effectiveness of the simplified test and treat intervention in
reducing delays to treatment and decreasing mortality.
Methods
Study Design
We used a pre- and post-intervention study design to evaluate the ability of a simplified HIV
test and treat intervention to reduce mortality among newly diagnosed HIV/AIDS cases. The
original design was one pre-intervention and one post-intervention phase. The design was
modified to have two pre-intervention and two post-intervention phases (Fig 1) based on sug-
gestions from peer review. Data from the “pre-intervention 2010” phase, the period from 1 Jan-
uary 2010 to 31 December 2010, and the “pre-intervention 2011” phase, the period from 1
January 2011 to 31 December 2011, were analyzed as the control arm, in comparison to the
“post-intervention 2012” phase, the period from 1 July 2012 to 30 June 2013, and the “post-
intervention 2013” phase, the period from 1 July 2013 to 30 June 2014. The period from 1 Janu-
ary 2012 to 30 June 2012 was treated as the “intervention transition period.”
Study Site
Guangxi Zhuang Autonomous Region is one of the provinces in China most heavily affected
by HIV/AIDS. In 2011, the overall mortality of HIV-positive individuals in Guangxi was 6.8%
compared to a national average mortality of 5%. The mortality in Guangxi was in the medium-
to-high range among the 31 provinces in China. However, Guangxi reported the highest abso-
lute number of HIV-related deaths, accounting for 22% of the deaths in all 31 provinces in
China. Late diagnosis (defined as diagnosis at CD4 count 200 cells/mm3 or no CD4 count
but clinical AIDS at the time of diagnosis of HIV infection) accounted for approximately one-
third of cases in Guangxi from 2007 to 2011. In 2011, nearly 70% of newly diagnosed cases had
an initial CD4 count 350 cells/mm3, and among the cases who died in 2011, 48% had been
diagnosed in the same calendar year [18]. About 79% of individuals who died of HIV-related
causes had never received ART, indicating that linkage to care was suboptimal. Zhongshan
County and Pubei County were selected as study sites because they had previously reported
high proportions of deaths occurring within the same calendar year of HIV/AIDS diagnosis. In
2011, the respective cumulative numbers of HIV cases in Zhongshan and Pubei were 625 and
986, and the main route of transmission was heterosexual contact. The 2011 mortality was
33.9% and 31.1% of newly diagnosed HIV/AIDS cases in Zhongshan and Pubei, respectively.
Study Participants
Eligibility criteria were the following: (1) participants were newly diagnosed HIV-positive
adults ( 18 y), (2) participants received a positive confirmation test at a study site (defined as
HIV Test and Treat to Reduce Mortality
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a WB test that met the national laboratory standards [19]), and (3) participants resided within
a study clinic’s catchment area. Participants were followed from the date of HIV confirmation
to the end of the study phase, and the follow-up duration for study participants ranged from 6
to 18 mo.
Standard-of-Care (Pre-Intervention) Procedures
HIV screening in Guangxi is available through health care facilities at the township level and
above (i.e., in ascending order, the levels township, county, city, provincial, and national).
Screening is available through self-referral for testing and provider-initiated testing (which is
routine in surgery departments, sexually transmitted infection clinics, and maternal care clin-
ics). Under China’s national policies, patients receive at least two screening tests in succession
(ELISA [enzyme-linked immunosorbent assay] or rapid test) and one WB test to confirm a
diagnosis of HIV infection. In the two study counties, patients are screened for HIV using a
rapid test at the initiating facility. If the initial screening test is positive, the patient is asked to
return to the same facility to give a second blood sample, which is sent to the local county Cen-
ter for Disease Control and Prevention (CDC) laboratory. This second screening test is ana-
lyzed using an ELISA test; if positive, the sample is sent to the city-level CDC laboratory for
Fig 1. Study design of the simplified HIV test and treat intervention. Pre-intervention consisted of the standard of care; there were six steps from the
enzyme immunoassay (EIA) screen to ART initiation, and the eligibility for ART was at CD4 count 350 cells/mm3. The simplified test and treat intervention
comprised three steps from the enzyme immunoassay screen to ART initiation, regardless of CD4 level. In all four phases, participants were followed for a
period of 6 to 18 mo, from the date of their WB confirmation results until 6 mo after the end of the recruitment phase in each study phase.
doi:10.1371/journal.pmed.1001874.g001
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confirmatory WB testing. About 29%–36% of patients who screen HIV-positive at health care
facilities fail to present for the second blood draw, marking the first drop-off in the care cas-
cade. WB results are usually available within 7–18 d, and if the WB test is positive, the patient
is asked to provide a third blood sample at the county CDC, which is transferred to the city
CDC laboratory for CD4 testing. After the CD4 results are available (typically within 7–18 d),
patients eligible for ART (CD4 count 350 cells/mm3) are asked to seek treatment at a sepa-
rate facility designated to provide ART, which is usually based at the county general hospital
[15].
Before treatment initiation, patients are expected to receive education and counseling on
ART and adherence, and a physical exam. A fourth blood sample is collected for baseline pre-
ART assessment, including kidney function, liver function, and other routine assessments.
Patients who are not eligible for ART at diagnosis are advised to undergo CD4 testing every 6
mo for ongoing reassessment of ART eligibility. In many counties, the diagnostic and treat-
ment initiation process requires patients to independently navigate multiple clinic visits, often
at different facilities. For patients who are ART-eligible at diagnosis, the usual timeline from
the initial screening to ART initiation is 2 to 4 mo. Treatment medication is provided free of
charge through the NFATP. Data for the pre-intervention phase were collected through retro-
spective records review.
Simplified Test and Treat Intervention Procedures
The simplified test and treat intervention incorporated (1) a streamlined, standardized time
frame for diagnosis and (2) expanded access to ART. These changes were enacted under the
leadership of the National Center for AIDS/STD Control and Prevention (NCAIDS) at the
Chinese Center for Disease Control and Prevention (China CDC), and included reorganization
of services [20], with an emphasis on linkage and integration of services. Other aspects of the
intervention included provider training and guidelines that accelerated treatment provision
[21].
Standardized framework for diagnosis: organizational structure and integration of ser-
vices. The simplified test and treat intervention framework designated activities to take place
on a predetermined schedule. Following a positive HIV screening test, the patient received
post-screening counseling (e.g., basic education on HIV/AIDS knowledge, the benefits of ART,
and the importance of encouraging partners to receive HIV testing) on the same day at the
same facility. At this time, the patient was scheduled for a visit at the HIV/AIDS clinic of the
county general hospital on the following Wednesday. The HIV/AIDS epidemiologist from the
county CDC and the chief physician of the county general hospital’s HIV/AIDS clinic were
proactively notified regarding the newly diagnosed patients that were expected to visit the
HIV/AIDS clinic the following Wednesday. Every Wednesday, an infectious disease physician
and nurses from the HIV/AIDS clinic of the county general hospital carried out medical con-
sultations for ART, blood sample collections for WB confirmation tests and CD4 cell count
tests, pretreatment physical examinations, liver and kidney function tests, treatment of oppor-
tunistic infections and other co-morbid conditions, and other services as appropriate. The
county CDC HIV/AIDS epidemiologist was based at the county general hospital each Wednes-
day to coordinate the delivery of blood samples from the county general hospital to the city
CDC laboratory for same-day WB and CD4 cell count testing and to confirm that patients who
screened HIV-positive within the past week presented for their scheduled visit. If a patient
failed to arrive at the Wednesday HIV/AIDS clinic visit, the epidemiologist informed the refer-
ring clinician to follow-up with the patient and to reschedule the HIV/AIDS clinic visit for the
following Wednesday. Every Friday, the city CDC delivered the HIV confirmation and CD4
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cell count results from the previous Wednesday’s samples to the county CDC HIV/AIDS epi-
demiologist, who transferred the results to the county general hospital. The county general hos-
pital was responsible for patient notification and all subsequent follow-up care. The county
CDC HIV/AIDS epidemiologist prepared a monthly report on all newly diagnosed HIV cases,
testing results, and treatment referral rates.
Expanded access to ART: training and guidelines. ART eligibility was expanded to
patients with a confirmed HIV diagnosis, irrespective of CD4 cell count, thereby superseding
the previous primary criterion for ART initiation of CD4 count 350 cells/mm3. The simpli-
fied test and treat intervention explicitly included a minimum of three counseling sessions
prior to treatment initiation. The first ART counseling session was provided by the staff of the
originating facility immediately after screening. The first counseling session emphasized the
importance of presenting to follow-up visits and ensured that the patients had the directions
and contact information for the county general hospital designated for providing ART services.
The second ART counseling session was provided by the county general hospital physician at
the time of collecting blood for HIV confirmatory and CD4 cell count testing. The third ART
counseling session was provided when patients received their HIV confirmatory and CD4 cell
count results. During each counseling session, all patients were strongly encouraged to initiate
ART promptly. Treatment medication was provided free of charge through the NFATP, which
is consistent with the standard-of-care procedure.
In order to implement the structural intervention described above, an initial planning meet-
ing was held with key stakeholders, including research staff from NCAIDS/China CDC, offi-
cials from the Guangxi Health Department, technical experts from Guangxi CDC, health
officials from the Pubei and Zhongshan county health departments, hospital directors and
HIV/AIDS clinicians from the two county general hospitals, county CDC directors, and county
CDC HIV/AIDS epidemiologists. A consensus was reached on the structural intervention com-
ponents and the corresponding implementation plan for the two study sites. Policy papers on
implementing the simplified test and treat intervention were issued by the two local county
health departments and distributed to all health facilities that provide HIV screening in the
two counties.
NCAIDS carried out training workshops for providers to review the new HIV care guide-
lines, practice mock exercises, strengthen communication skills, and reinforce professional
expectations. Clinicians who conduct HIV screening tests were also intensively trained on pro-
viding post-screening counseling. A handbook was issued to all providers on HIV testing, treat-
ment, and prevention, and educational materials were prepared for distribution to newly
diagnosed HIV-positive patients. To monitor the intervention, site supervisors from NCAIDS
were stationed in the two study sites for the first 2 mo of the intervention. Afterwards, site visits
were conducted monthly to monitor adherence to the intervention protocol. The total cost for
the study intervention was approximately US$14,525.75.
Data Management
The local county CDC HIV/AIDS epidemiologists are legally responsible for following up on
all HIV-positive patients to record demographic information, eligibility for ART, and present
status (i.e., in regular HIV care, lost to follow-up, migrated out of the county, or deceased)
every 6 mo. Physicians providing ART are required to collect ART-related information, includ-
ing medication side effects and ART status (i.e., engaged on ART, dropped out of ART, lost to
follow-up, migrated out of the county, or deceased) every 3 mo and success or failure of ART
based on viral load testing once a year. In the pre-intervention phase, per the standard of care,
the CDC HIV/AIDS epidemiologists collected data independently of the ART-providing
HIV Test and Treat to Reduce Mortality
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clinicians. In the intervention phase, the HIV/AIDS epidemiologists collaborated with clini-
cians to record patient data using standardized case report forms. Data were subsequently
entered into the national HIV/AIDS case reporting and NFATP databases. These two databases
are subsystems of China’s Comprehensive Response Information Management System
(CRIMS), a national web-based real-time data system for HIV care and follow-up, which has
been previously described [22]. An HIV/AIDS dataset for Pubei and Zhongshan covering 1
January 2010 to 31 December 2014 was downloaded from CRIMS. The study participants in
the pre-intervention 2010 phase comprised patients newly diagnosed as HIV-positive between
1 January 2010 and 31 December 2010 and were followed until 30 June 2011. The study partici-
pants in the pre-intervention 2011 phase comprised patients newly diagnosed as HIV-positive
between 1 January 2011 and 31 December 2011 and were followed until 30 June 2012. The
study participants in the post-intervention 2012 phase were patients newly diagnosed as HIV-
positive between 1 July 2012 and 30 June 2013 and were followed until 31 December 2013. The
study participants in the post-intervention 2013 phase were patients newly diagnosed as HIV-
positive between 1 July 2013 and 30 June 2014 and were followed until 31 December 2014. In
all four phases, each participant was followed for a duration between 6 and 18 mo. We used
data from the 12 mo preceding the pre-intervention 2011 phase and from the 12 mo after the
post-intervention 2012 phase to assess potential secular time trends independent of the inter-
vention, based on suggestions from peer review.
Statistical Analysis
Survival times were calculated as the time from HIV confirmation until death or the last fol-
low-up (at which point survival times were censored). The number of days (median, interquar-
tile range [IQR]) from HIV-positive screening to HIV confirmatory testing, the total number
of deaths, and mortality rates were tabulated, stratified by study phase. The overall proportions
receiving ART and receiving ART within 30 d of HIV confirmation in each phase were com-
pared by chi-square tests. Kaplan-Meier curves describing survival and ART initiation were
compared by log-rank tests. Cox proportional hazards multivariate regressions were used to
calculate hazard ratios (HRs) for the effect of the study phase on mortality after adjustment for
baseline demographic risk factors. We estimated adjusted hazard ratios (aHRs) and 95% confi-
dence intervals (CIs) from the Cox regressions, using the pre-intervention 2011 phase as a ref-
erence group. In addition, we performed an analysis where we further adjusted for variables
that could have been modified by the intervention (baseline CD4 or clinical status, and ART
initiation). ART initiation was treated as a time-dependent covariate, which took the value zero
until the time that a patient first received ART. The proportional hazards assumption for all
covariates was assessed by testing the Martingale residuals, and we found no evidence that this
assumption was violated. Because the treatment eligibility criteria changed between the pre-
intervention and post-intervention study phases, we conducted additional analyses among the
subset of individuals with CD4 count 350 cells/mm3 or with clinical AIDS so that the treat-
ment-related outcomes were comparable between the two pre-intervention and two post-inter-
vention phases. Statistical analyses were performed using SAS (version 9.1.3, SAS Institute).
We estimated the actual cost of implementing the intervention, including the cost of the
training of local health workers, incentives for health workers for timely referral and initiation
of patients on ART, monitoring of the implementation, and educational materials. We
excluded any costs that were specific to research. The number of additional patients receiving
ART because of the intervention was estimated for the initial year of the intervention (post-
intervention 2012 phase) and for the second year of the intervention (post-intervention 2013
phase), based on differences in the ART coverage rate compared to that in the pre-intervention
HIV Test and Treat to Reduce Mortality
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2011 phase. The number of deaths prevented because of the intervention was estimated for the
post-intervention 2012 phase and for the post-intervention 2013 phase, based on the differ-
ences in overall mortality compared to that in the pre-intervention 2011 phase. We estimated
the cost both as a total for the program and as an incremental cost per incremental patient
achieving the primary outcome.
Among the above, the approach to stratifying the proportional hazard assumptions, assess-
ing potential secular trends, and conducting the cost analysis emerged from the review process.
Ethics
The study protocol was reviewed and approved by the Institutional Review Board of NCAIDS,
China CDC (#X120717220). All patients who screened HIV-positive were requested to give
their written informed consent for the use of their de-personalized data in future epidemiologi-
cal analysis. No additional study-specific written informed consent was obtained. None of the
participants opted out. There was no incentive for study participants.
Results
As shown in Fig 2, a total of 281 and 339 newly diagnosed HIV-positive patients were included
in the pre-intervention 2010 and pre-intervention 2011 phases, respectively, and 215 and 199
patients in the post-intervention 2012 and post-intervention 2013 phases, respectively. Among
the 281 patients in the pre-intervention 2010 phase, 76 (27.0%) enrolled in ART, and 75
(26.7%) died, including two deaths following ART initiation. Among the 339 participants in
the pre-intervention 2011 phase, 165 (48.7%) enrolled in ART, and 90 (26.5%) died, including
15 deaths following ART initiation. During the post-intervention 2012 phase, 196 out of 215
(91.2%) individuals enrolled in ART, and 21 (9.8%) individuals died, including 12 deaths fol-
lowing ART initiation. During the post-intervention 2013 phase, 177 out of 199 (89%) patients
enrolled in ART, and 20 (10.0%) patients died, including 13 deaths following ART initiation.
Median participant follow-up was 8.77 mo (IQR 6.0–12.2) for the post-intervention 2013
phase and 9.2 mo (IQR 5.9–12.2) for the post-intervention 2012 phase, compared to 7.9 mo
(IQR 5.6–11.2) for the pre-intervention 2011 phase and 7.33 mo (IQR 4.1–11.1) for the pre-
intervention 2010 phase. In the intervention transition period (not included in Fig 2), 111
patients were diagnosed with HIV infection, 77 (69.4%) enrolled in ART, and 22 died (19.8%),
including seven deaths following ART initiation.
Of the total 1,034 participants (Table 1), 746 (72%) were male, and the median age was 48 y
(IQR 36–60). Nearly all participants had a middle school education or below (95.6%) and were
employed as farmers (90.6%). Over half of the individuals were married or partnered (56.5%).
The participants who were enrolled during the four phases were not statistically significantly
different on any baseline demographic characteristics. The predominant mode of HIV trans-
mission was heterosexual contact, and this remained consistent throughout the study. Among
111 patients diagnosed in the intervention transition period (not included in Table 1), 87
(78.4%) were male, median age was 51 y (IQR 38–60), and 109 cases were infected by hetero-
sexual transmission, and two cases via injecting drug use.
In the pre-intervention 2010 and pre-intervention 2011 phases, 67% (median CD4
count = 243 cells/mm3, IQR 75–384) and 60.5% (median CD4 count = 219 cells/mm3, IQR 77–
403) of participants had a baseline CD4 cell count within 30 d of HIV confirmation, respec-
tively. This value was statistically significantly higher in the post-intervention 2012 phase
(97.7%, median CD4 count = 220 cells/mm3, IQR 69–379, all p< 0.001[i.e., for all comparisons
between a pre- and post-intervention phase]) and in the post-intervention 2013 phase (97%,
median CD4 count = 178 cells/mm3, IQR 53–330, all p< 0.001). In the pre-intervention 2010
HIV Test and Treat to Reduce Mortality
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Fig 2. Number of HIV diagnoses, ART initiations, and deaths in the pre-intervention 2010, pre-intervention 2011, post-intervention 2012, and post-
intervention 2013 phases in Guangxi, China.
doi:10.1371/journal.pmed.1001874.g002
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Table 1. Characteristics of newly diagnosed HIV cases in the pre-intervention 2010, pre-intervention 2011, post-intervention 2012, and post-inter-
vention 2013 phases in Guangxi, China.
Characteristic Pre-Intervention
2010 (Jan 2010–Dec
2010), n = 281 (1)
Pre-Intervention
2011 (Jan 2011–Dec
2011), n = 339 (2)
Post-Intervention
2012 (Jul 2012–Jun
2013), n = 215 (3)
Post-Intervention
2013 (Jul 2013–Jun
2014), n = 199 (4)
p-Value (1)
versus (2)
p-Value (2)
versus (3)
p-Value (3)
versus (4)
n or
Median
Percent
or IQR
n or
Median
Percent or
IQR
n or
Median
Percent or
IQR
n or
Median
Percent or
IQR
Demographic variables
Gender 0.210 0.532 0.742
Male 195 69% 251 74% 154 71% 146 73%
Female 86 31% 88 26% 61 29% 53 27%
Age (years) 46 31–62 52 33–63 46 37–58 49 37–59 0.131 0.281 0.446
Mode of HIV infection 0.708 0.656 0.342
Heterosexual contact 266 95% 324 96% 208 97% 196 98%
Other 15 5% 15 4% 7 3% 3 2%
Educational attainment 0.120 0.813 0.632
Middle school or below 264 94% 328 97% 207 96% 189 95%
High school or above 17 6% 11 3% 8 4% 10 5%
Occupation 0.445 0.373 0.319
Farmer 246 88% 304 90% 198 92% 189 95%
Other 35 12% 35 10% 17 8% 10 5%
Marital status 0.255 0.136 0.164
Single, divorced, or widowed 116 41% 156 46% 85 40% 93 47%
Married or partnered 165 59% 183 54% 130 60% 106 53%
Outcome variables
Median baseline CD4 count (cells/
mm3)
243 75–384 219 77–403 220 69–379 178 53–330 0.672 0.462 0.078
CD4 subgroups <0.001 <0.001 —
200 cells/mm3 80 28% 135 40% 100 47% 111 56% <0.001 0.008 0.005
201–350 cells/mm3 50 18% 59 17% 52 24% 47 24% 0.723 0.005 0.949
>350 cells/mm3 57 20% 93 27% 59 27% 41 21% 0.011 0.857 0.020
Missing CD4 and reported as AIDS case 58 21% 43 13% 2 1% 0 0% 0.009 <0.001
Missing CD4 and reported as non-AIDS
case
36 13% 9 3% 2 1% 0 0%
Time from HIV confirmation to CD4
testing (days)
28 11–145 14 6–42 1 0–4 0 0–-1 <0.001 <0.001 <0.001
Number of patients with CD4 testing
within 30 d of HIV confirmation
189 67% 205 60.5% 210 97.7% 193 97% 0.080 <0.001 0.663
Number of ART initiations (regardless
of CD4 cell count)
76 27% 165 48.7% 196 91.2% 177 89% <0.001 <0.001 0.511
Number of ART initiations within 30 d
of HIV confirmation
24 9% 68 20.1% 175 81.4% 160 80% <0.001 <0.001 0.707
Time from HIV screening to HIV
confirmation (days) for ART-initiated
patients
11 6–22 11 7–18 7 3–10 6 3–9 0.896 <0.001 0.923
Time from HIV confirmation to ART
initiation (days) for ART-initiated
patients
53 27–141 43 15–113 5 2–12 5 2–13 0.036 <0.001 0.823
Overall mortality 75 26.7% (75/
281)
90 26.5% (90/
339)
21 9.8% (21/
215)
20 10.1% (20/
199)
0.968 <0.001 0.923
Mortality of ART-initiated patients 2 2.6% (2/
76)
15 9.1% (15/
165)
12 6.1% (12/
196)
13 7.3% (13/
177)
0.050 0.286 0.526
Mortality of untreated patients 73 35.6% (73/
205)
75 43.1% (75/
174)
9 47.4% (9/
19)
7 31.8% (7/
22)
0.030 0.722 0.145
Number of ART initiations (CD4  350
cells/mm3 or missing CD4 but
reported as AIDS case)
74 39.4% (74/
188)
146 61.6%
(146/237)
144 93.5%
(144/154)
142 89.9%
(142/158)
<0.001 <0.001 0.246
(Continued)
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and pre-intervention 2011 phases, 34% and 16% of patients failed to obtain CD4 testing at any
time point, compared to 2% and 0% in the post-intervention 2012 and post-intervention 2013
phases (all p< 0.001), respectively. The median time from HIV confirmatory testing to CD4
testing was 28 d (IQR 11–145) in the pre-intervention 2010 phase and 14 d (IQR 6–42) in the
pre-intervention 2011 phase, compared to 1 d (IQR 0–4) in the post-intervention 2012 phase
(all p< 0.001) and 0 d (IQR 0–1) in the post-intervention 2013 phase (all p< 0.001). In the
intervention transition period (not included in Table 1), 93 (83.8%, median CD4 count = 264
cells/mm3, IQR 75–433) had a baseline CD4 cell count within 30 d of HIV confirmation, and
11 (10%) of patients failed to obtain CD4 testing at any time point. The median time from HIV
confirmatory testing to CD4 testing was 6 d (IQR 4–13).
In the pre-intervention 2010 and pre-intervention 2011 phases, 27% and 48.7% of the total
participants initiated ART, respectively, compared to 91.2% and 89% in the post-intervention
2012 and post-intervention 2013 phases, respectively (all p< 0.001). Among individuals with
CD4 count 350 cells/mm3 or missing their CD4 count but reported as diagnosed with AIDS,
39.4% in the pre-intervention 2010 phase and 61.6% in the pre-intervention 2011 phase initi-
ated ART, compared to 93.5% in the post-intervention 2012 phase and 89.9% in post-interven-
tion 2013 phase (all p< 0.001). For patients who initiated ART, the median time from HIV
screening to confirmatory testing was 11 d (IQR 6–22) in the pre-intervention 2010 phase and
11 d (IQR 7–18) in the pre-intervention 2011 phase, compared to 7 d (IQR 3–10) in the post-
intervention 2012 phase and 6 d (IQR 3–9) in the post-intervention 2013 phase (all p< 0.001).
The median time from HIV confirmatory testing to treatment initiation was 53 d (IQR 27–
141) in the pre-intervention 2010 phase and 43 d (IQR 15–113) in the pre-intervention 2011
phase, compared to 5 d (IQR 2–12) in the post-intervention 2012 phase and 5 d (IQR 2–13) in
the post-intervention 2013 phase (all p< 0.001). In the intervention transition period (not
included in Table 1), 77 cases (69.4%) initiated ART, and the median time from HIV confirma-
tory testing to treatment initiation was 25 d (IQR 7–97).
A total of 228 deaths occurred over the entire study observation period, with a crude mortal-
ity of 26.7% in the pre-intervention 2010 phase and 26.5% in the pre-intervention 2011 phase,
compared to 9.8% in the post-intervention 2012 phase and 10.1% in the post-intervention
2013 phase (all p< 0.001) and 19.8% in the intervention transition period (not included in
Table 1). Among individuals with CD4 count 350 cells/mm3 or missing CD4 count but diag-
nosed with AIDS, 198 deaths occurred, with mortality of 39.9% in the pre-intervention 2010
phase and 35.0% in the pre-intervention 2011 phase, compared to 13.0% in the post-interven-
tion 2012 phase and 12.7% in the post-intervention 2013 phase (all p< 0.001). Reassuringly,
the primary outcome variable of overall mortality was quite consistent within the two pre-
Table 1. (Continued)
Characteristic Pre-Intervention
2010 (Jan 2010–Dec
2010), n = 281 (1)
Pre-Intervention
2011 (Jan 2011–Dec
2011), n = 339 (2)
Post-Intervention
2012 (Jul 2012–Jun
2013), n = 215 (3)
Post-Intervention
2013 (Jul 2013–Jun
2014), n = 199 (4)
p-Value (1)
versus (2)
p-Value (2)
versus (3)
p-Value (3)
versus (4)
n or
Median
Percent
or IQR
n or
Median
Percent or
IQR
n or
Median
Percent or
IQR
n or
Median
Percent or
IQR
Mortality of patients with CD4  350
cells/mm3 or missing CD4 but
reported as AIDS case
75 39.9% (75/
188)
83 35.0% (83/
237)
20 13.0% (20/
154)
20 12.7% (20/
158)
0.160 <0.001 0.915
Mortality of ART-initiated patients 2 2.7% (2/
74)
15 10.3% (15/
146)
12 8.3% (12/
144)
13 9.2% (13/
142)
0.032 0.108 0.719
Mortality of untreated patients 73 64.0% (73/
114)
68 74.7% (68/
91)
8 80.0% (8/
10)
7 43.8% (7/
16)
0.009 <0.001 0.021
doi:10.1371/journal.pmed.1001874.t001
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intervention phases, at 26.7% and 26.5%, respectively. Mortality was 9.8% and 10.1% in the
two post-intervention phases, respectively. We observed 22 deaths among 113 HIV cases
newly diagnosed during the 6 mo of the intervention transition period, with a crude mortality
of 19.5% (22/113), which falls in between the values of the two pre-intervention phases and
the two post-intervention phases. We also calculated the mortality rates for the two pre-
intervention phases, the intervention transition period, and the two post-intervention phases,
and there were 3.5, 3.4, 2.5, 1.2, and 1.2 deaths/100 person-years, respectively.
The HIV care cascades by study phase are shown in Fig 3. Our study focused on the period
between HIV-positive confirmation and death. Among all patients in the pre-intervention
2010 and pre-intervention 2011 phases, 33.5% and 15.3% of patients were lost to follow-up
between HIV diagnosis and CD4 testing, respectively. A further 39.5% and 36.0% of patients
were lost before ART initiation, respectively, and 26.7% and 26.5% of patients died, respec-
tively. In contrast, in the post-intervention 2012 and post-intervention 2013 phases, only 1.9%
and 0.0% of patients were lost to follow-up between HIV diagnosis and CD4 testing, respec-
tively; an additional 7.0% and 11.1% of patients were lost before ART initiation, respectively,
and 9.8% and 10.1% of patients died, respectively. Among individuals with CD4 count 350
cells/mm3 or missing CD4 but diagnosed with AIDS, 30.9% of patients in the pre-intervention
2010 phase and 18.1% of patients in the pre-intervention 2011 phase were lost to follow-up
between HIV diagnosis and CD4 testing, a further 29.8% and 20.3% were lost before ART initi-
ation, respectively, and 39.9% and 35.0% died, respectively. Among comparable patients in the
post-intervention 2012 and post-intervention 2013 phases, 1.3% and 0.0% were lost to follow-
up between HIV diagnosis and CD4 testing, respectively, a further 5.2% and 10.1% were lost
before ART initiation, respectively, and 13.0% and 12.7% died, respectively. In the intervention
transition period (not included in Fig 3), among all newly diagnosed cases, 9.9% of patients
were lost to follow-up between HIV diagnosis and CD4 testing, a further 20.7% were lost before
ART initiation, and 19.8% died. Among individuals with CD4 count 350 cells/mm3 or miss-
ing CD4 but diagnosed with AIDS, 12.9% of patients were lost to follow-up between HIV diag-
nosis and CD4 testing, a further 11.4% were lost before ART initiation, and 31.4% died.
Patients in the two post-intervention phases had significantly higher survival rates over the
follow-up period than those in the two pre-intervention phases (all p< 0.001; Fig 4). As shown
in Fig 5, within 90 d of HIV confirmation, ART coverage in the post-intervention 2012 and
post-intervention 2013 phases was similar and was 2.5 times the coverage in the pre-interven-
tion 2011 phase and 4.8 times the coverage in the pre-intervention 2010 phase for all newly
diagnosed patients, and 2.0 times and 3.3 times, respectively, for patients with CD4
count 350 cells/mm3 or missing CD4 but reported as AIDS cases.
Table 2 describes factors associated with mortality for study participants pooled from the
two pre-intervention and the two post-intervention phases. In univariate analysis, factors asso-
ciated with death were being male (HR 2.604, 95% CI 1.758–3.856, p< 0.001), every 10-y
increase in age (HR 1.258, 95% CI 1.155–1.371), CD4 count 200 cells/mm3 or AIDS (HR
15.344, 95% CI 8.918–26.402, p< 0.001), and receiving ART (HR 0.231, 95% CI 0.162–0.328,
p< 0.001). The simplified test and treat intervention was statistically strongly associated with a
decreased risk for mortality (HR 0.361, 95% CI 0.224–0.580, p< 0.001, for post-intervention
2012; HR 0.367, 95% CI 0.226–0.603, p< 0.001, for post-intervention 2013).
In the multivariate proportional hazards model, after adjusting for age and gender, the sim-
plified test and treat intervention was significantly associated with decreased mortality com-
pared to pre-intervention 2011 (aHR 0.385, 95% CI 0.239–0.620, p< 0.001, for post-
intervention 2012; aHR 0.380, 95% CI 0.233–0.618, p< 0.001, for post-intervention 2013).
When the variables that were potentially modified by the intervention were also included in
the regression model (i.e., CD4 testing, CD4 cell counts, and ART initiation), we found that the
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Fig 3. Cascade of confirmed HIV diagnosis, CD4 testing, ART initiation, andmortality during the pre-intervention 2010, pre-intervention 2011, post-
intervention 2012, and post-intervention 2013 phases in Guangxi, China. (A) For all HIV cases. (B) For individuals with CD4 count 350 cells/mm3 or
missing CD4 but reported as AIDS cases.
doi:10.1371/journal.pmed.1001874.g003
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Fig 4. Kaplan-Meier survival curves for newly diagnosed HIV cases in the pre-intervention 2010, pre-
intervention 2011, post-intervention 2012, and post-intervention 2013 phases in Guangxi, China. (A)
For all HIV cases. (B) For individuals with CD4 count 350 cells/mm3 or missing CD4 but reported as AIDS
cases.
doi:10.1371/journal.pmed.1001874.g004
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Fig 5. Kaplan-Meier curves for ART initiation for newly diagnosed HIV cases in the pre-intervention
2010, pre-intervention 2011, post-intervention 2012, and post-intervention 2013 phases in Guangxi,
China. (A) For all HIV cases. (B) For individuals with CD4 count 350 cells/mm3 or missing CD4 but
reported as AIDS cases.
doi:10.1371/journal.pmed.1001874.g005
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intervention was no longer significantly associated with mortality (aHR 1.034, 95% CI 0.611–
1.752, p = 0.900, for post-intervention 2012; aHR 0.882, 95% CI 0.517–1.504, p = 0.644, for
post-intervention 2013). This result suggests that the impact of the intervention on mortality
was meditated through changes in these other variables.
We repeated the analyses for the subset of individuals with CD4 count 350 cells/mm3 or
clinical AIDS (Table 3). Under the multivariable model that controlled for gender and age, the
simplified test and treat intervention was significantly associated with reduced mortality com-
pared to pre-intervention 2011 (aHR 0.369, 95% CI 0.226–0.603, p< 0.001, for post-interven-
tion 2012; aHR = 0.361, 95% CI 0.221–0.590, p< 0.001, for post-intervention 2013). As was
the case for all HIV cases, after adjustment for variables that were specifically changed by the
intervention, the intervention’s effect on mortality was no longer statistically significant (aHR
1.033, 95% CI 0.601–1.774, p = 0.907, for post-intervention 2012; aHR 0.915, 95% CI 0.534–
1.567, p = 0.746, for post-intervention 2013).
The cost analysis results are shown in Table 4. The total cost of the simplified test and treat
intervention implementation was US$14,525.75, with a cost of US$13,750.00 and US$775.75
for the first and second year, respectively. The unit cost for an additional patient receiving ART
attributable to the intervention was US$83.80, with a cost of US$147.46 and US$9.69 for the
first and second year, respectively (Table 5). The unit cost of a death prevented because of the
intervention was US$234.52, with US$420.08 in the initial year and US$26.56 in the second
year.
Discussion
Our results show that a simplified HIV test and treat intervention incorporating a streamlined,
standardized time frame for diagnosis and expanded access to ART, irrespective of CD4 cell
Table 2. Mortality among all newly diagnosed HIV cases during the pre-intervention 2010, pre-intervention 2011, post-intervention 2012, and post-
intervention 2013 phases, based on Coxmodel analysis.
Characteristic Number of
Deaths
Observed
Person-
Months
Mortality Rate
(Events/100
Person-Months)
HR (95% CI) p-Value aHR-1 (95% CI) p-Value aHR-2 (95% CI) p-Value
Study phase
Pre-intervention 2010 (n = 281) 75 2,113 3.5 1.025 (0.754–1.392) 0.877 1.137 (0.835–1.547) 0.415 0.952 (0.697–1.301) 0.758
Pre-intervention 2011 (n = 339) 90 2,629 3.4 1 1 1
Post-intervention 2012 (n = 215) 21 1,816 1.2 0.361 (0.224–0.580) <0.001 0.385 (0.239–0.620) <0.001 1.034 (0.611–1.752) 0.900
Post-intervention 2013 (n = 199) 20 1,650 1.2 0.367 (0.226–0.603) <0.001 0.380 (0.233–0.618) <0.001 0.882 (0.517–1.504) 0.644
Gender
Female 29 2,540 1.1 1 1 1
Male 177 5,668 3.1 2.604 (1.758–3.856) <0.001 2.552 (1.720–3.786) <0.001 1.952 (1.314–2.898) 0.001
Every 10-y increase in age 206 8,209 2.5 1.258 (1.155–1.371) <0.001 1.211 (1.115–1.315) <0.001 1.132 (1.035–1.238) 0.007
Baseline CD4 count or clinical
status
CD4  200 cells/mm3 or AIDS 192 3,754 5.1 15.344 (8.918–
26.402)
<0.001 19.286 (11.132–
33.414)
<0.001
CD4 > 200 cells/mm3 or non-AIDS 14 4,455 0.3 1 1
ART initiation status
Yes 42 5,590 0.8 0.231 (0.162–0.328) <0.001 0.139 (0.089–0.217) <0.001
No 164 2,618 6.3 1 1
HR: HR based on univariate Cox model; aHR-1: aHR based on multivariate Cox model adjusted for demographic variables (age and gender), but not
adjusted for intervention-changeable variables (baseline CD4 count or clinical status, ART initiation); aHR-2: aHR based on multivariate Cox model
adjusted for both demographic variables (age and gender) and intervention-changeable variables (baseline CD4 count or clinical status, ART initiation).
doi:10.1371/journal.pmed.1001874.t002
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count, resulted in a significant increase in ART coverage within 90 d of diagnosis of HIV infec-
tion, from below 36% to over 90% among all newly diagnosed HIV/AIDS cases, and from
under 47% to over 93% among newly diagnosed cases with CD4 count 350 cells/mm3 or
missing CD4 but reported as AIDS cases. The simplified HIV test and treat intervention was
also associated with significantly reduced overall mortality, from about 26% to fewer than 10%.
Our results also show that the cost of the intervention was quite low, and mostly accrued in
the initial year, as we set up the intervention. The unit cost per additional patient receiving
ART declined to US$9.69 in the second year. Similarly, the unit cost per death prevented attrib-
utable to the intervention was US$234.52 over the study period, and it declined to US$26.56 in
the second year of the study. Based on these results, we feel that the simplified test and treat
intervention represents an effective and sustainable structural intervention that requires very
little further investment once it is set up.
China is committed to providing universal access to HIV testing and treatment in concor-
dance with the WHO Treatment 2.0 strategy [1]. However, optimizing the cascade of HIV
care, particularly during pre-treatment follow-up and monitoring, remains a key challenge. To
address this issue, NCAIDS, China CDC, prioritized the identification, implementation, and
assessment of new strategies for improved engagement in HIV testing and treatment.
Table 3. Mortality among newly diagnosed treatment-eligible HIV cases (with CD4 count 350 cells/mm3 or missing CD4 but reported as AIDS
cases) during the pre-intervention 2010, pre-intervention 2011, post-intervention 2012, and post-intervention 2013 phases, based on Coxmodel
analysis.
Characteristic Number
of Deaths
Observed
Person-
Months
Mortality Rate
(Events/100
Person-Months)
HR (95% CI) p-Value aHR-1 (95% CI) p-Value aHR-2 (95% CI) p-Value
Study phase
Pre-intervention
2010 (n = 188)
75 1,363 5.5 1.160 (0.849–1.585) 0.353 1.293 (0.944–1.772) 0.110 1.036 (0.753–1.424) 0.829
Pre-intervention
2011 (n = 237)
83 1,746 4.8 1 1 1
Post-intervention
2012 (n = 154)
20 1,332 1.5 0.353 (0.211–0.560) <0.001 0.369 (0.226–0.603) <0.001 1.033 (0.601–1.774) 0.907
Post-intervention
2013 (n = 158)
20 1,282 1.6 0.344 (0.211–0.561) <0.001 0.361 (0.221–0.590) <0.001 0.915 (0.534–1.567) 0.746
Gender
Female 28 1,646 1.7 1 1 1
Male 170 4,077 4.2 2.312 (1.550–3.449) <0.001 2.384 (1.596–3.562) <0.001 1.915 (1.280–2.866) 0.002
Every 10-y
increase in age
198 5,723 3.5 1.194 (1.047–1.361) <0.001 1.166 (1.066–1.275) 0.001 1.128 (1.028–1.237) 0.011
Baseline CD4
count or clinical
status
CD4  200 cells/
mm3 or AIDS
192 3,754 5.1 15.405 (6.834–
34.725)
<0.001 15.116 (6.696–
34.176)
<0.001
CD4 > 200 cells/
mm3 or non-AIDS
6 1,970 0.3 1 1
ART initiation
Yes 42 4,658 0.9 0.154 (0.108–0.221) 0.144 (0.092–0.225)
No 156 1,065 14.6 1 <0.001 1 <0.001
HR: HR based on univariate Cox model; aHR-1: aHR based on multivariate Cox model adjusted for demographic variables (age and gender), but not
adjusted for intervention-changeable variables (baseline CD4 or clinical status, ART initiation); aHR-2: aHR based on multivariate Cox model adjusted for
both demographic variables (age and gender) and intervention-changeable variables (baseline CD4 or clinical status, ART initiation).
doi:10.1371/journal.pmed.1001874.t003
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Few other studies have addressed the test and treat strategy in Asia. Our findings show that
the implementation of a simplified test and treat intervention was associated with a significant
decrease in mortality rate. Furthermore, this is the first study to our knowledge to show that a
structural intervention to streamline HIV testing procedures and to expand treatment eligibil-
ity can have a substantial impact on the full HIV care cascade and patient mortality. We
Table 4. Cost analysis of implementation of the intervention in Guangxi, China, 2012–2014.
Variable Unit
Cost
Post-Intervention 2012 Post-Intervention 2013 Total
Cost
Number of Units or
Individuals
Cost Number of Units or
Individuals
Cost
Training workshop for local health workers (1 d/
county)
Three trainers: ground transportation 16.13 3 × 2 person-trips 96.77
Three trainers: per diem/hotel 69.35 3 × 2 person-days 416.13
80 health workers in Pubei 29.03 80 2,322.58
92 health workers in Zhongshan 29.03 92 2,670.97
Subtotal 5,506.45 5,506.45
Monthly monitoring by provincial staff (two staff/
visit, 4 d/visit)
Ground transportation 16.13 2 × 7 person-trips 225.81 2 × 4 person-trips 20.81
Per diem/hotel 69.35 2 × 28 person-days 3,883.87 2 × 16 person-days 357.96
Subtotal 4,109.68 378.77 4,488.45
Training/educational materials
Handbook for health workers 1.61 300 483.87
Educational materials for patients 0.50 2,000 1,000.00
Subtotal 1,483.87
Health worker incentives
Referring a patient to ART 8.06 211 1,701.61 199 258.84
Initiating a patient on ART 4.84 196 948.39 177 138.14
Subtotal 2,650.00 396.98 3,046.98
Total 13,750.00 775.75 14,525.75
All costs are in US dollars.
doi:10.1371/journal.pmed.1001874.t004
Table 5. Unit cost per patient receiving ART, unit cost per additional patient receiving ART because of
the intervention, and unit cost per death prevented because of intervention in Guangxi, China, 2012–
2014.
Variable Post-Intervention 2012
(Total Cost = 13,750.00)
Post-Intervention 2013
(Total Cost = 775.75)
Average Unit
Cost
Number of
Patients or
Deaths
Unit
Cost
Number of
Patients or
Deaths
Unit
Cost
Patients receiving ART 196 70.15 177 4.38 38.94
Additional patients receiving
ART because of intervention
93 147.46 80 9.69 83.80
Deaths prevented because of
intervention
33 420.08 29 26.56 234.52
All costs are in US dollars.
doi:10.1371/journal.pmed.1001874.t005
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present evidence that a reconceptualization of HIV testing and treatment policies can have a
dramatic effect on patient outcomes, even in the absence of new diagnostic technologies. Our
findings provide program-based evidence to support widespread implementation of this inter-
vention in China and to support similar test and treat strategies elsewhere. Given the size of
China’s HIV-positive population, the simplified test and treat intervention at scale could
streamline the diagnostic process for hundreds of thousands of patients.
Over the pre-intervention phases, 33%–40% of patients failed to complete CD4 testing
within 30 d of HIV confirmation. This is concerning because the CD4 count is the primary
determinant of ART eligibility under the standard of care. While the proportion of patients
who had CD4 count> 350 cells/mm3 remained consistent throughout the study (27%), we
noted a higher proportion of patients who had CD4 count 200 cells/mm3 or who were
reported as AIDS cases during the pre-intervention phases. This suggests that under the stan-
dard-of-care practice (i.e., the pre-intervention study phases), patients who failed to complete
CD4 testing were more likely to have lower CD4 cell counts. These results reinforce previous
findings that late HIV diagnosis remains a crucial challenge for HIV care providers in China
and globally [14,23–25].
Complex testing procedures increase the risk for LTFU. Under the standard of care, the
steps of HIV testing and treatment initiation were not co-located. Rather, patients often had to
attend several medical facilities, such as the original facility that provided screening (e.g., town-
ship clinic), the local CDC, and the county hospital, in order to confirm the diagnosis and to
begin treatment. This promotes structural delays in the initiation of treatment and increases
the likelihood of attrition. The simplified test and treat intervention provided an opportunity
to streamline the procedures from a patient-centered perspective. After the initial screening, all
care visits occurred at a single location, the county general hospital. Furthermore, providing
concurrent CD4 and WB confirmatory testing reduced the total number of visits, and thus
delays, before beginning ART. Our data suggest that the simplified test and treat intervention
had significant overall success in expanding access to CD4 testing and promoting initiation of
ART, with the consequent favorable impact of decreased mortality.
A small proportion of patients (8.8%–11%) in the two post-intervention phases still failed to
initiate treatment, which may be due to stigma, competing needs, insufficient understanding of
ART’s benefits, or voluntary refusal of treatment [6,26–29]. To minimize this proportion, the
simplified test and treat intervention has multiple built-in opportunities during the pre-treat-
ment process to deliver pre-ART counseling and to encourage ART engagement. In our study,
the overwhelming majority of patients were willing to initiate ART, irrespective of CD4 cell
count. The initiation of ART for all HIV/AIDS cases is likely to be facilitated in the future as
emerging global guidelines evolve to embrace the recently released results of the TEMPRANO
[30] and START [31] studies, which definitively confirmed that immediate initiation of ART,
irrespective of CD4 cell count, is associated with significant reductions in clinical disease pro-
gression [32].
We noted that the number of newly diagnosed patients in the two pre-intervention phases
(281 and 339) was higher than the number in the two post-intervention phases (215 and 199)
and that the mortality in the two pre-intervention phases (26.7% and 26.5%) was also higher
than in the two post-intervention phases (9.8% and 10.1%). The number of people who are
diagnosed per year depends on the regional HIV incidence, the performance of HIV testing
programs, and individual willingness to be tested. In 2010 (immediately prior to the pre-inter-
vention 2010 phase), Guangxi launched a province-wide 5-y public campaign to promote HIV
testing. This may have led to a sharp increase in the number of people being tested and diag-
nosed in 2010 and 2011 (i.e., the two pre-intervention phases). The later stages of the HIV test-
ing promotion campaign in 2012–2013 coincided with the intervention phase. We suspect
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that, by this time, there may have been a lower proportion of undiagnosed HIV cases, which
led to fewer newly diagnosed individuals in the intervention phase compared to the pre-
intervention phase. Compared to the post-intervention 2012 phase (n = 215), the post-
intervention 2013 phase experienced an additional but modest decrease in the number of new
HIV cases (n = 199).
The concomitant testing promotion campaign in Guangxi may have potentially uncovered
the sickest individuals first, who would have been a part of the pre-intervention outcomes, and
gradually identified healthier patients, who went into the post-intervention phases. This could
have contributed to the observed reduction in mortality in our study. However, the fact that
the observed mortality went from above 35% before to below 13% after the implementation of
the simplified test and treat intervention among the subset of patients with CD4 count 350
cells/mm3 or missing CD4 but reported as AIDS cases is reassuring in this regard.
We noticed that from the pre-intervention 2010 phase to the pre-intervention 2011 phase
the proportion of patients initiating ART within 30 d of HIV confirmation increased from 9%
to 20.1% and that overall ART initiation increased from 27% to 48.7%; in other words, ART
initiation doubled, but mortality remained unchanged from the pre-intervention 2010 phase to
the pre-intervention 2011 phase. This might be explained if the pre-intervention increase in
ART initiation comprised mainly healthier patients, while the sickest patients continued to die
at the same rate. The simplified test and treat intervention is likely to speed up treatment initia-
tion effectively but may also change who gets treated. Please also note that though ART initia-
tion doubled from the first to the second pre-intervention phase, ART coverage was still very
low and therefore not sufficient to favorably impact mortality. The improved ART coverage
from the first to the second pre-intervention phase should not undermine the effect of the
intervention—although it may change in part the “mechanism” of the effect and the nature of
the intervention. The fact that ART coverage within 30 d of HIV diagnosis increased sharply to
81.4% in the post-intervention 2012 phase and remained at 80% in the post-intervention 2013
phase is unlikely to be due solely to time secular trends; rather, we believe that the intervention
was a major contributor to the increase in ART coverage.
In 2013, WHO changed its ART guidelines to recommend ART initiation for patients with
CD4 count 500 cells/mm3, rather than at the previously recommended threshold of 350
cells/mm3 [33]. It is estimated that these revised guidelines have increased the total number of
ART-eligible people in low- and middle-income countries from 16.7 million to 25.8 million
[34]. In resource-limited settings, using CD4 testing as the basis for HIV staging increases the
demands on clinic and laboratory staff compared to clinical staging. However, some jurisdic-
tions in China have already embraced universal ART eligibility, irrespective of CD4 cell count,
as proposed in our study [35]. Such a policy maximizes the benefits of ART in reducing HIV
disease progression to AIDS and premature death and at the same time reduces HIV transmis-
sion and thereby maximizes the potential of the treatment as prevention strategy [36–39].
The HIV epidemic in China presents unique challenges. Because of the country’s size, a low
national prevalence of<1% still translates into a very large HIV-positive population of approx-
imately 780,000 [40]. In Guangxi, the epidemic is characterized by a high proportion of late-
diagnosed cases, and delayed ART initiation due to the additional time required for progressing
through the sequential steps of the cascade of care. With a simplified cascade, both diagnosis
and ART initiation occurred earlier, resulting in enhanced engagement in ART and decreased
mortality. We designed the simplified test and treat intervention specifically for the context of
China’s HIV epidemic and health care structure, and, as a result, the specifics of the interven-
tion procedures and results may not be fully generalizable to other countries. Nevertheless, the
intervention targets the issues of late diagnosis and procedural barriers that delay care, which
are common challenges in HIV programs worldwide. We believe that our experience is
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beneficial to the global community in that it provides evidence in support of the feasibility and
clinical benefits of the test and treat strategy, particularly for settings where late diagnosis and
treatment are common.
Although the pre-intervention/post-intervention study design allowed for control of some
hospital-based characteristics, assumptions about the simplified test and treat intervention’s
causal effects must be treated with caution. Internal validity is affected by history, maturation,
and Hawthorne threats. Implementing a package of interventions also prevents the evaluation
of the relative contribution of each of the individual components on the overall observed effect.
Late diagnosis (CD4 count 200 cells/mm3) of HIV is a key barrier to reducing mortality and
morbidity, which we could not evaluate fully in this study. In the intervention phase, we used
data collected over the course of standardized care, while outcomes in the two pre-intervention
phases were assessed retrospectively. The pre-intervention data monitoring was less thorough
than the data monitoring in the two post- intervention phases, which may have had an impact
on data quality. During the two pre-intervention phases, reporting of outcomes such as mortal-
ity may have been delayed, resulting in a lower reported baseline mortality and an underesti-
mation of the impact of the intervention.
China has begun expanding the simplified test and treat intervention to 12 additional coun-
ties in nine provinces. Further evaluation of the feasibility and acceptability of this intervention
will provide additional evidence for national and international policymakers. Early diagnosis in
conjunction with prompt linkage to care could be a game changer for the HIV epidemic in
China. Our results demonstrate that a simplified HIV testing approach combined with
expanded access to ART, irrespective of CD4 count, can lead to a substantial reduction in mor-
tality. Our findings support increased integration of HIV testing and treatment to optimize the
potential individual and public health benefits of ART.
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Editors' Summary
Background
Every year, about 2.1 million people (mostly living in resource-limited countries) are
newly infected with HIV, the virus that causes AIDS and that has killed 39 million people
over the past three decades. HIV, which is usually transmitted through unprotected sex
with an infected individual, gradually destroys CD4 lymphocytes and other immune sys-
tem cells, leaving HIV-positive individuals susceptible to other infections. Early in the
AIDS epidemic, most HIV-positive individuals died within ten years of infection. Then, in
1996, effective antiretroviral therapy (ART) became available, and, for people living in
high-income countries, HIV became a chronic condition. But ART was expensive, so
HIV/AIDS remained largely untreated and fatal in resource-limited countries. In 2003, the
international community began to work towards achieving universal ART coverage. By
2013, about 12.9 million people living with HIV (a third of all HIV-positive people) had
access to ART, and the rate of AIDS-related deaths had fallen by a third from its 2005
peak.
WhyWas This Study Done?
Unfortunately, in many countries, late diagnosis of HIV infection, incomplete linkage to
care after diagnosis, and high rates of loss to follow-up before and after ART initiation
remain major barriers to effective HIV/AIDS treatment and to maximization of the pre-
ventative benefits of ART: as well as keeping HIV-positive people healthy, ART also
reduces their chances of transmitting HIV to a sexual partner. Here, the researchers inves-
tigate whether a simplified “test and treat” intervention can reduce HIV/AIDS mortality
(death) rates in China by reducing these barriers. Currently, CD4 testing is offered to peo-
ple in China only after an initial HIV diagnosis has been confirmed using a second type of
test. This standard-of-care policy introduces a delay into ART initiation because a CD4
count below 350 cells/μl blood is the primary determinant of eligibility for treatment
through the Chinese national free ART program. By contrast, the simplified test and treat
intervention, which is designed to be completed within a week of the patient’s first positive
HIV test result, incorporates immediate HIV confirmatory testing, pre-ART CD4 testing,
pre-treatment counseling, and ART initiation regardless of CD4 count.
What Did the Researchers Do and Find?
The researchers followed about 1,000 patients who tested positive for HIV at health care
facilities in two counties in Guangxi (one of the Chinese provinces most heavily affected
by HIV/AIDS) in two 12-month pre-intervention phases, during which patients followed
the standard-of-care process, and two 12-month post-intervention phases, during which
patients were offered the simplified test and treat intervention. About 65% and 97% of the
patients received baseline CD4 testing during the pre-intervention and post-intervention
phases, respectively. Following the structural intervention, the time from HIV confirma-
tion to ART initiation decreased from around 50 days to five days, and the proportion of
individuals who initiated ART increased from below 36% to above 90% among all the
patients and from below 47% to above 93% among patients eligible for treatment under
the standard-of-care policy. Notably, the mortality rate decreased from about 26% to
about 10% among all the study participants following the intervention, and from about
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37% to about 13% among the participants eligible for ART under the standard-of-care pol-
icy. Finally, the researchers estimated that the cost of each death prevented by the inter-
vention was about US$234.52 over the study period; importantly, most of this cost was
accrued during the initial year of the intervention.
What Do These Findings Mean?
These findings indicate that, in the two Chinese counties involved in this study, the simpli-
fied test and treat intervention—which incorporated a streamlined, standardized time
frame for HIV diagnosis and expanded access to ART—promoted successful engagement
in care among HIV-positive individuals and was associated with a 62% reduction in mor-
tality. Moreover, the intervention required very little further investment once it had been
set up and should, therefore, be sustainable. Because the design of the simplified test and
treat intervention took into account the characteristics of the HIV epidemic and the health
care structure in China, these findings may not be fully generalizable to other countries. In
addition, reliance on a pre-intervention/post-intervention study design, rather than a con-
trolled trial, may limit the accuracy of these findings. Nevertheless, these results suggest
that the implementation of integrated HIV testing and immediate access to ART regard-
less of CD4 count has the potential to optimize the individual and public health impacts of
ART by ensuring that fewer patients are lost along the multistage continuum of HIV test-
ing and treatment.
Additional Information
This list of resources contains links that can be accessed when viewing the PDF on a device
or via the online version of the article at http://dx.doi.org/10.1371/journal.pmed.1001874.
• Information is available from the US National Institute of Allergy and Infectious Dis-
eases on HIV infection and AIDS
• NAM/aidsmap provides basic information about HIV/AIDS, summaries of recent
research findings on HIV care and treatment, and personal stories about living with
HIV/AIDS
• Information is available from Avert, an international AIDS charity, on many aspects of
HIV/AIDS, including information on universal access to ART and on HIV/AIDS in
China; Avert also provides personal stories about living with HIV/AIDS
• TheWorld Health Organization provides information on all aspects of HIV/AIDS (in
several languages), including its Consolidated Guidelines on the Use of Antiretroviral
Therapy for Treating and Preventing HIV Infection, its recently released consolidated
guidelines on HIV testing, and information on the WHO/UNAIDS Treatment 2.0
strategy, an initiative to expand access to HIV testing and ART
• The UNAIDS Fast-Track Strategy to End the AIDS Epidemic by 2030 provides up-to-
date information about the AIDS epidemic and efforts to halt it, including progress
towards universal access to antiretroviral therapy
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